Bolt Biotherapeutics (BOLT) News Today → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free BOLT Stock Alerts $1.16 -0.04 (-3.35%) (As of 05:12 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBolt Biotherapeutics (NASDAQ:BOLT) Share Price Passes Above 200 Day Moving Average of $1.09americanbankingnews.com - April 25 at 3:34 AMContrasting Blueprint Medicines (NASDAQ:BPMC) & Bolt Biotherapeutics (NASDAQ:BOLT)americanbankingnews.com - April 15 at 2:16 AMBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 22 at 6:43 AMBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 21 at 4:05 PMBolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conferenceglobenewswire.com - February 27 at 7:00 AMBuy Rating Affirmed for GlycoMimetics Amidst Phase 3 Progress and Breakthrough Therapy Designation for Uproleselanmarkets.businessinsider.com - January 4 at 7:57 AMBolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®finance.yahoo.com - December 5 at 7:28 AMPromising Clinical Trial Results and Strong Financial Outlook Propel Buy Rating for Bolt Biotherapeuticsmarkets.businessinsider.com - November 11 at 9:52 AMBolt Biotherapeutics Inc Ordinary Shares BOLTmorningstar.com - November 9 at 7:45 PMBolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 9 at 7:45 PMBolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congressfinance.yahoo.com - October 23 at 12:45 PMBolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancersfinance.yahoo.com - October 17 at 8:07 AMBolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancersfinance.yahoo.com - September 28 at 7:54 AMBolt Biotherapeutics to Participate in September Investor Conferencesfinance.yahoo.com - September 5 at 8:29 PMDynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimatesmsn.com - August 3 at 8:26 PMUS0977021049.SG - Bolt Biotherapeutics Inc.finance.yahoo.com - June 17 at 11:56 AMBolt Biotherapeutics (BOLT) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - May 26 at 7:38 AMSVB Leerink Upgrades Bolt Biotherapeutics (BOLT)msn.com - May 13 at 8:01 AMHC Wainwright & Co. Reiterates Bolt Biotherapeutics (BOLT) Buy Recommendationmsn.com - May 13 at 8:01 AMJonesTrading Reaffirms Their Buy Rating on Bolt Biotherapeutics (BOLT)markets.businessinsider.com - May 12 at 4:20 PMBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - May 12 at 4:43 AMBolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meetingfinance.yahoo.com - April 26 at 1:52 PMInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last yearfinance.yahoo.com - April 11 at 8:23 AMBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updatefinanznachrichten.de - March 30 at 10:05 AMBolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meetingfinance.yahoo.com - March 14 at 5:25 PMBOLT.O - | Stock Price & Latest News | Reutersreuters.com - January 21 at 1:51 PMHere's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situationfinance.yahoo.com - January 4 at 12:28 PMInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last yearfinance.yahoo.com - November 2 at 4:10 PMBolt Biotherapeutics to Present at Stifel 2022 Healthcare Conferencefinance.yahoo.com - November 1 at 10:53 AMBolt Biotherapeutics Inc Ordinary Sharesmorningstar.com - September 10 at 12:35 AMBolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conferencefinance.yahoo.com - August 31 at 11:39 AMBolt Biotherapeutics (NASDAQ:BOLT), Earnings Estimates, EPS, and Revenuebenzinga.com - August 12 at 6:36 PMThe past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitablefinance.yahoo.com - May 26 at 8:54 AMBolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlightsfinance.yahoo.com - March 30 at 6:36 PMBolt Biotherapeutics GAAP EPS of -$0.73 misses by $0.04, revenue of $0.51Mseekingalpha.com - March 30 at 6:36 PMBolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022finance.yahoo.com - March 8 at 7:37 PMBolt Biotherapeutics, Inc. (BOLT)finance.yahoo.com - February 10 at 8:17 PMBolt Biotherapeutics (NASDAQ:BOLT) Downgraded by Zacks Investment Researchmarketbeat.com - February 7 at 6:20 PMBolt Biotherapeutics to Participate in Upcoming February Conferencesfinance.yahoo.com - February 2 at 9:03 AMBolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumorsfinance.yahoo.com - January 6 at 10:13 AMMorgan Stanley Downgrades Bolt Biotherapeutics (NASDAQ:BOLT) to Equal Weightmarketbeat.com - January 6 at 8:17 AMBolt Biotherapeutics, Inc. (NASDAQ:BOLT) Given Average Recommendation of "Buy" by Analystsmarketbeat.com - January 2 at 6:21 AMBolt Biotherapeutics Shares Rise 12% After CFO Buys 5,000 Sharesmarketwatch.com - December 11 at 11:03 PMBolt Biotherapeutics Stock Halves on Mediocre Trial Datafinance.yahoo.com - December 6 at 5:33 PMWhy Bolt Biotherapeutics Stock Crashed Todayfinance.yahoo.com - December 6 at 5:33 PMBolt Biotherapeutics Interim Data Shows BDC-1001 Cancer Treatment Well-Toleratedmarketwatch.com - December 6 at 7:32 AMBolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021finance.yahoo.com - December 6 at 7:32 AMBolt Biotherapeutics Announces Changes to its Board of Directorsfinance.yahoo.com - November 19 at 8:13 AMBolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meetingfinance.yahoo.com - November 12 at 8:34 AMBolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlightsfinance.yahoo.com - November 9 at 7:44 AM Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers. Find out what it is and see how you can get in with just a few dollars. BOLT Media Mentions By Week BOLT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BOLT News Sentiment▼0.670.41▲Average Medical News Sentiment BOLT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BOLT Articles This Week▼20▲BOLT Articles Average Week Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Fortress Biotech News Emergent BioSolutions News Regulus Therapeutics News Aadi Bioscience News Rockwell Medical News Ocuphire Pharma News Xilio Therapeutics News NextCure News NRx Pharmaceuticals News CalciMedica News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BOLT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
